HSA
FPRX

Hussman Strategic Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Hussman Strategic Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-115,000
Closed -$5.76M – 242
2016
Q4 		$5.76M Sell
115,000
-10,000
-8% -$525K 1.15% 30
2016
Q3 		$6.56M Buy
+125,000
New +$5.97M 1.08% 38

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Hussman Strategic Advisors's FPRX Position: Q1 2017 in Review

Hussman Strategic Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 115,000 shares — an estimated $5.76M sold.

Hussman Strategic Advisors first reported a position in FPRX in Q3 2016 and held it in 2 quarters. The position peaked at $6.56M in Q3 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Hussman Strategic Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Hussman Strategic Advisors sold 115,000 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $5.76M.
  • Hussman Strategic Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Hussman Strategic Advisors's Five Prime Therapeutics, Inc. position peaked at $6.56M in Q3 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Hussman Strategic Advisors's 13F filing for Q1 2017, filed 1 May 2017.